Cationic Nanoparticles Containing Cationic Peptide Cargo Synergistically Induce Cellular Reactive Oxygen Species and Cell Death in HepG2 Cells
- 54 Downloads
Previous reports have suggested that cationic nanoparticles (NPs)-consisting of cationic monovalent lipids, such as 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), induce reactive oxygen species (ROS) and ROS-mediated toxicity in cells. We have investigated the effects of DOTAP-based NPs (dNPs) containing cationic peptide (cPep) cargo on HepG2 cells. Compared with cargo-free dNPs, treatment with cPep-dNPs containing peptides composed of lysine (or arginine) residues further stimulated the production of cellular ROS. Concomitantly, the cell viability was more decreased by the treatment with cPep-dNPs. A cationic peptide composed of 6–10 lysine residues showed the most effective synergistic induction of ROS. However, dNPs encapsulating neutral peptide consisted of alanine residues did not elicit synergistic ROS generation or cell death. The present study suggests that a cationic peptide-NP system might effectively induce cancer cell death through the production of ROS in the absence of any other therapeutic cancer reagents.
KeywordsDOTAP DOTMA HepG2 Nanoparticle Cationic peptide Reactive oxygen species
This research was carried out with the support of Veterinary Biochemical Practice Program for undergraduate students 2014–2017, Chonnam National University.
Compliance with Ethical Standards
Conflict of interest
The authors declares that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- Bhagwat SV, Vijayasarathy C, Raza H, Mullick J, Avadhani NG (1998) Preferential effects of nicotine and 4-(N-methyl-N-nitrosamine)-1-(3-pyridyl)-1-butanone on mitochondrial glutathione S-transferase A4-4 induction and increased oxidative stress in the rat brain. Biochem Pharmacol 56:831–839CrossRefGoogle Scholar
- Chen Y, Bathula SR, Yang Q, Huang L (2010) Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol 130:2780–2798Google Scholar